Loading organizations...
§ Private Profile · 8 The Green Dover, Delaware 19901, USA
Health technology company transforming cancer care with personalized lifestyle medicine via a tech-enabled platform.
Based in the United States, Complement 1 is a health technology company that provides a personalized lifestyle medicine platform and daily coaching services for cancer patients, survivors, and high-risk individuals. The company's clinically validated software integrates physical activity, nutrition, and somatic practices alongside standard oncology treatments to improve patient outcomes and reduce healthcare costs by up to 30 percent for its network of employers and providers. Operating with a B2B model, the startup has achieved a 90 percent adherence rate with its coaching program and secured platform adoption across multiple top cancer centers. To scale its operations and commercial reach, the enterprise recently raised $16 million in an oversubscribed seed funding round led by venture capital firms Owl Ventures and Blume Ventures. Complement 1 was founded in 2024 by Karan Bajaj and Trupti Mukker.
Complement 1 has raised $16.0M across 1 funding round.
Complement 1 has raised $16.0M in total across 1 funding round.
Complement 1 has raised $16.0M in total across 1 funding round.
Complement 1's investors include Owl Ventures, Blume Ventures, Costanoa Ventures, Creandum, Equal Ventures, foobar.vc, Hyde Park Venture Partners, Jungle Ventures, Lightbank, Powerhouse Ventures, Preface Ventures, StartHer.
Complement 1 has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $16M Seed | OWL Ventures, Blume Ventures | Costanoa Ventures, Creandum, Equal Ventures, Foobar.vc, Hyde Park Venture Partners, Jungle Ventures, Lightbank, Powerhouse Ventures, Preface Ventures, Starther, Union Square Ventures, Ashish Agrawal, Kunal Shah, Sahil Lavingia | Announced |
Complement 1 is a health technology company founded in 2024 that builds a clinically validated, tech-enabled lifestyle modification platform for cancer patients, survivors, and high-risk individuals.[1][2][3] It delivers personalized daily 1:1 CoActive Coaching combined with evidence-based interventions in physical activity, nutrition, and somatic practices, integrating seamlessly with conventional oncology care to improve patient outcomes, quality of life, and reduce costs by up to 30% for employers, providers, and insurers.[1][2][3] The platform serves cancer centers, health plans, employers, and patients, addressing gaps in oncology by achieving over 90% user adherence, with clinical results showing 37% fewer treatment side effects, 18% less pain, and 27% better sleep.[2][3][4] In May 2025, it raised a $16M oversubscribed seed round led by Owl Ventures and Blume Ventures, signaling strong growth momentum as it emerges from stealth to scale nationwide.[1][2][3]
Complement 1 was founded in 2024 in the U.S., emerging from stealth in 2025 with a mission to transform cancer care through lifestyle medicine, backed by leading oncologists and scientific research including meta-studies on lifestyle impacts on cancer recurrence and mortality.[1][2][3][5] Key figures include Trupti Mukker, Co-founder and COO, who has highlighted the company's focus on combining high-tech personalization with high-touch coaching to fill critical oncology gaps.[4] While specific founder backgrounds beyond Mukker are not detailed in available sources, the idea stemmed from evidence showing lifestyle modifications' role in improving cancer outcomes, leading to the development of the first such clinically validated platform.[2][3] Early traction came via clinical trials validating its efficacy, culminating in the $16M seed funding on May 13, 2025, from Owl Ventures, Blume Ventures, and healthcare angels, enabling U.S. expansion.[1][2][3][4]
Complement 1 stands out in oncology health tech through these key strengths:
Complement 1 rides the wave of personalized medicine and lifestyle interventions in oncology, fueled by rising cancer incidence rates and meta-studies proving lifestyle changes reduce recurrence, mortality, and side effects.[2][3][4] Timing is ideal amid growing demand for holistic, cost-effective care as health systems face escalating oncology expenses—its 30% cost reductions align with payer and employer priorities.[1][3] Market forces like AI advancements enable its personalization engine, while post-pandemic emphasis on patient-centered tech supports high-adherence models over generic apps.[2] By partnering with cancer centers and insurers, it influences the ecosystem, pioneering scalable lifestyle medicine that could standardize complementary oncology protocols and inspire similar platforms in chronic disease management.[2][3]
Complement 1 is poised to expand its coaching infrastructure, AI engine, and partnerships across U.S. cancer centers, health plans, and employers, enhancing its platform for broader adoption.[2][3] Trends like AI personalization, value-based care, and holistic oncology will propel growth, potentially capturing a slice of the $200B+ global cancer care market as evidence mounts. Its influence may evolve from niche innovator to ecosystem standard-setter, empowering patients while delivering ROI—watch for Series A and major health system integrations to solidify its transformative role in cancer care.[1][2][3][4]